Novartis agreed to acquire an experimental breast-cancer drug from Synnovation Therapeutics for up to $3 billion.
The following table highlights multi-billion dollar deals where established giants moved to buy specialized oncology companies: Target Biotech Value (Up to) Primary Cancer Focus Kelonia Therapeutics $7 Billion Blood Cancer (CAR-T) Abbott Exact Sciences $21 Billion Early Screening/Diagnostics Gilead Tubulis $5 Billion Ovarian & Lung Cancer (ADCs) Gilead Arcellx $7.8 Billion Multiple Myeloma Johnson & Johnson Halda Therapeutics $3.1 Billion Prostate Cancer Genmab Merus $8 Billion Head and Neck Cancer Novartis Synnovation (Pikavation) $3 Billion Breast Cancer Why These Deals are Happening buy cancer
: Analysts maintain an Overweight rating , forecasting significant upside potential. If you're looking for more info, are you interested in: Specific types of cancer treatments (like CAR-T or ADCs)? Financial analysis of these stocks? Clinical trial details for these new acquisitions? Financial analysis of these stocks
Major pharmaceutical companies have been on a massive spending spree in 2025 and 2026, acquiring innovative biotech firms to bolster their cancer-treatment pipelines. : Large firms like Eli Lilly and Novartis
: Large firms like Eli Lilly and Novartis are racing to replace revenue from older drugs that are nearing patent expiration.
Financial analysts currently view certain cancer biotech stocks as strong opportunities:
Novartis to Buy Breast-Cancer Drug From Synnovation ... - WSJ